Results 141 to 150 of about 13,028,724 (400)

A systematic approach to cardiovascular risk factor control in primary care: a report from the strokebelt [PDF]

, 2003
William H. Bestermann
openalex   +1 more source

Financial Variables and Systematic Risk

, 2017
The objective of this study is to examine the relationship among financial determinants and systematic risk of cement industry. Five financial variables are utilized as components, i.e.
Rashed Nawaz, W. Ahmed, Imran, Sabeela Sabir, Muhammad Arshad, T. Rani, A. Khan   +6 more
semanticscholar   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

SP540PROSPECTIVE CONTROLED STUDY OF SYSTEMATIC ULTRASOUND MAPPING IN PATIENTS WITH HIGH RISK OF FAILURE IN FISTULA CREATION [PDF]

, 2016
José Ibeas, Joaquim Vallespín, Sara Rioja, N. Lenis Cordoba, J. C. Albillos Merino, Jos R Fortuño, Xavier Vinuesa, A. Martínez Mateo, Ángel Rodríguez-Jornet   +8 more
openalex   +1 more source

Evaluating the Dynamic Nature of Market Risk [PDF]

This study examines the systematic risk present in major crops for the United States and three corn-belt states. An index of commodities is used in conjunction with cash receipts to generate dynamic estimates of the systematic risk for each crop and ...
Baker, Timothy G., Hubbs, Todd, Kuethe, Todd H.   +2 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Risk Transmission of Trade Price Fluctuations from a Nickel Chain Perspective: Based on Systematic Risk Entropy and Granger Causality Networks. [PDF]

Entropy (Basel), 2022
Zhou X, Zheng S, Zhang H, Liu Q, Xing W, Li X, Han Y, Zhao P.   +7 more
europepmc   +1 more source

Chapter 7: Systematic Reviews of Etiology and Risk

JBI Manual for Evidence Synthesis, 2020
Sandeep Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, Raluca Sfetc, Marian Currie, K. Lisy, R. Qureshi, Patrick Mattis, P. Mu   +10 more
semanticscholar   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Improving Risk Assessment in Clinical Trials: Toward a Systematic Risk-Based Monitoring Approach. [PDF]

Curr Ther Res Clin Exp, 2021
Fneish F, Schaarschmidt F, Fortwengel G.
europepmc   +1 more source